Works matching IS 17562872 AND DT 2015 AND VI 7 AND IP 3
Results: 6
Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27).
- Published in:
- Therapeutic Advances in Urology, 2015, v. 7, n. 3, p. 105, doi. 10.1177/1756287215574479
- By:
- Publication type:
- Article
Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.
- Published in:
- Therapeutic Advances in Urology, 2015, v. 7, n. 3, p. 125, doi. 10.1177/1756287215577329
- By:
- Publication type:
- Article
The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.
- Published in:
- Therapeutic Advances in Urology, 2015, v. 7, n. 3, p. 135, doi. 10.1177/1756287215576647
- By:
- Publication type:
- Article
Tadalafil therapy for erectile dysfunction following prostatectomy.
- Published in:
- Therapeutic Advances in Urology, 2015, v. 7, n. 3, p. 146, doi. 10.1177/1756287215576626
- By:
- Publication type:
- Article
A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.
- Published in:
- Therapeutic Advances in Urology, 2015, v. 7, n. 3, p. 116, doi. 10.1177/1756287215574480
- By:
- Publication type:
- Article
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma.
- Published in:
- Therapeutic Advances in Urology, 2015, v. 7, n. 3, p. 152, doi. 10.1177/1756287215574457
- By:
- Publication type:
- Article